Testing Menstrual Blood Samples to Screen for Cervical Cancer
Studies a self-collected menstrual blood test for HPV to screen women for cervical cancer.
Key facts
- Who runs it
- Zhongnan Hospital
- Where
- Wuhan, ChinaSee the site
- Trial code
- Registry title
- Cervical Cancer Screening with NGS-HPV Technology Based on Menstrual Blood
- Status
- Recruiting
- People taking part
- 10,000 people, planned
- Started
- 1 Sept 2021
- Expected to end
- 31 Mar 2028
- Type of study
- Observational
- Record updated
- 18 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women who plan to have cervical cancer screening and have regular periods. It tests menstrual blood self-sampling to find HPV.
- Age
- 20 Years to 60 Years
- Sex
- Women only
Main reasons for not taking part
- No periods (amenorrhea) or menopause
- Infection of the genital tract
- Refusing to take part in the study
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- plan to undergo cervical screening
- with regular menstruation (21-35 days)
- agree to participate in this study and have signed an informed consent form
Who cannot take part
- suffering from genital tract infection
- with amenorrhea or menopause
- refuse to participate in this study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 60 years old?
Where in China
- Department of Gynecologic OncologyWuhan, ChinaContact: Zheng Hu, doctorTaking people
About the trial
What the trial wants to find out
Our study is a population-based, cross-sectional study. This study is conducted to recruit cervical cancer screening participants to evaluate the application value of using high-throughput sequencing technology to detect HPV in menstrual blood for cervical cancer screening. Our study is designed as a two-phase study :
Read full original descriptionShow less
Phase I : This phase, which will be preparing to recruit 5,000 participants, evaluates the accuracy of menstrual blood (MB) self-sampling for detecting cervical intraepithelial neoplasia grade two or worse (CIN2+) in the general population, with a secondary objective to evaluate the Minipad as a special device to collect MB.
Phase II : This phase, which will continue to recruit toward the 10,000-participant target, will evaluate additional molecular markers (specifically DNA methylation) to optimize alternative triage methods for HPV-positive women in menstrual blood (MB) self-sampling. This phase aims to further reduce unnecessary colposcopies while maintaining high sensitivity for CIN2+ detection.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Cervical Cancer Screening with NGS-HPV Technology Based on Menstrual Blood
- Plain-language title
- Testing Menstrual Blood Samples to Screen for Cervical CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06082765, who can take part
- Publications
- Testing menstrual blood for human papillomavirus during cervical cancer screening in China: cross sectional population based study.BMJ (Clinical research ed.), 2026
- Record updated
- 18 February 2025